Gerald M. Lieberman
Gerald M. Lieberman's purchase track record
How the stock did after each of Gerald M. Lieberman's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/22/2023 | ENTX | $17K | +143.1% | +210.8% | +14.9% |
| 8/21/2023 | ENTX | $12K | +20.7% | +73.6% | +13.1% |
| 11/14/2022 | ENTX | $28K | +60.7% | +80.7% | +4.5% |
| 7/21/2022 | ENTX | $33K | -55.8% | -53.4% | -2.5% |
| 1/18/2022 | ENTX | $8K | +3.9% | -48.9% | -14.0% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Entera Bio gets new coverage from Guggenheim and Cantor. Guggenheim has started coverage of Entera Bio, giving it a buy rating and a target price of $11. Cantor Fitzgerald also began coverage, assigning an overweight rating. These new ratings come as the stock trades near its 52‑week low and shows a moderate RSI of 40, indicating room for movement.
Transaction History
| TEVA | ▲ Buy | Option Exercise | 14,492 | — | 6/5/2026 | View on chart |
| ENTX | ▲ Buy | Grant | 38,294 | $0 | 1/1/2026 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 9,632 | — | 6/6/2025 | View on chart |
| ENTX | ▲ Buy | Option Exercise | 23,952 | $24K | 4/1/2025 | View on chart |
| ENTX | ▲ Buy | Grant | 10,717 | $0 | 1/15/2025 | View on chart |
| ENTX | ▲ Buy | Grant | 11,269 | $0 | 10/2/2024 | View on chart |
| ENTX | ▲ Buy | Grant | 27,261 | $0 | 8/27/2024 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 21,108 | — | 6/15/2024 | View on chart |
| ENTX | ▲ Buy | Open Market | 23,952 | $17K | 12/22/2023 | View on chart |
| ENTX | ▲ Buy | Open Market | 20,000 | $12K | 8/21/2023 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 15,810 | — | 8/4/2023 | View on chart |
| ENTX | ▲ Buy | Open Market | 34,000 | $19K | 11/14/2022 | View on chart |
| ENTX | ▲ Buy | Open Market | 4,000 | $2K | 11/14/2022 | View on chart |
| ENTX | ▲ Buy | Open Market | 4,000 | $2K | 11/14/2022 | View on chart |
| ENTX | ▲ Buy | Open Market | 4,000 | $2K | 11/14/2022 | View on chart |
| ENTX | ▲ Buy | Open Market | 4,000 | $2K | 11/14/2022 | View on chart |
| ENTX | ▲ Buy | Open Market | 19,491 | $33K | 7/21/2022 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 14,479 | — | 6/14/2022 | View on chart |
| ENTX | ▲ Buy | Open Market | 700 | $2K | 1/18/2022 | View on chart |
| ENTX | ▲ Buy | Open Market | 700 | $2K | 1/18/2022 | View on chart |
| ENTX | ▲ Buy | Open Market | 700 | $2K | 1/18/2022 | View on chart |
| ENTX | ▲ Buy | Open Market | 700 | $2K | 1/18/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Teva Receives FDA Approval for Weltruza, Announces R&D Day
Teva Pharmaceutical Industries secured FDA approval for Weltruza, a once‑monthly long‑acting injectable for schizophrenia. The approval follows the company’s announcement of an R&D day in New York City, where it will discuss its pipeline and future research plans. Barclays raised its price target to $47, citing the new product launch and potential growth in the schizophrenia market. These developments add fresh catalysts to Teva’s outlook.
Teva Receives FDA Approval for Weltruza, Announces R&D Day. Teva Pharmaceutical Industries secured FDA approval for Weltruza, a once‑monthly long‑acting injectable for schizophrenia. The approval follows the company’s announcement of an R&D day in New York City, where it will discuss its pipeline and future research plans. Barclays raised its price target to $47, citing the new product launch and potential growth in the schizophrenia market. These developments add fresh catalysts to Teva’s outlook.